VK
Viking Therapeutics
VKTX · NASDAQ
$32.13 -1.14% (-$0.37)
1M -3.25%
Market Cap $3.81B
P/E Ratio -
Div. Yield -
ROE 94.56%
Bulios Fair Price
$18.42
42.7% downside
Current Price
$32.13
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VKTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 9.34x
PEG N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 63.83%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 94.56%
ROA 102.47%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 4.72x
Int. coverage -66,848.50x
Debt/Equity 0.01x
Stability
37 /100
Moderate EPS volatility 120.52%
Profitable years 0
Beta 0.68x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VKTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Lian
Employees
65
Headquarters
San Diego
Upcoming events
28 OCT
Earnings
Upcoming earnings report